Marc Darrow, MD, JD
Could a Wharton’s jelly or umbilical cord blood product help an ankle that remains painful or weak? Early research offers reasons to investigate these approaches, but the product and the diagnosis both matter. An injection aimed at the wrong structure is unlikely to answer the underlying problem.
Pain on the outside of the ankle is often described as tendinitis. Sometimes that is the right diagnosis. Sometimes the problem involves a ligament, a tendon that moves out of position, a joint injury, or several structures at once. Choosing treatment starts with finding out which problem is present.
Two questions from a recent Living Pain-Free radio discussion illustrate this distinction. Heidi described about a month of left ankle pain, a feeling of weakness, and discomfort that sometimes seemed to affect her knee. She located the ankle pain outside, just below the bone. Stephen called about a friend in his early 70s who played tennis almost daily and had experienced ankle pain and tendinitis for years despite previous evaluations.
Neither description establishes a diagnosis. My starting point is to examine the ankle and identify the painful structure before recommending a treatment. The name of an injection should follow that assessment.
What can hurt on the outside of the ankle?
The peroneal tendons run behind the outer ankle bone. They help control the foot during walking and sport. Tendon irritation, a tear, or instability of the tendons can produce lateral ankle symptoms. Nearby lateral ligaments help restrain excessive ankle movement. Their injury can coexist with a tendon problem. The ESSKA-AFAS consensus on peroneal disorders emphasizes this diagnostic overlap and the importance of identifying the specific pathology. (1)
The location and behavior of symptoms help direct the examination. Pain behind the outer ankle bone raises different questions from pain in front of it. Snapping, repeated giving way, swelling, or pain with particular movements should be described specifically rather than grouped together under “weak ankle.”
A feeling of weakness also needs clarification. Does the ankle unexpectedly roll? Is the person avoiding loading because it hurts? Has balance deteriorated? These experiences may require different treatment priorities.
Why tennis and other activities may keep provoking symptoms
Tennis involves repeated acceleration, stopping, sideways movement, and changes of direction. A player may tolerate straight-line walking yet have pain when pushing sideways or recovering from a wide shot. Returning to the same schedule without understanding the limitation can make it difficult to judge whether the ankle is improving.
This does not mean the player must abandon the sport permanently. It means the assessment should include the demands of the activity the person wants to resume. The relevant question is whether the ankle can tolerate those demands consistently.
Does the MRI tell the whole story?
Imaging can help identify a tendon tear, ligament injury, or another structural problem. Ultrasound can also provide a dynamic view of selected tendons. The peroneal consensus recognizes roles for both ultrasound and MRI; the choice depends on the suspected problem and available expertise. (1)
The scan and examination should answer the same clinical question. A finding on a report does not automatically identify the source of pain. Equally, an examination should not be used to dismiss an important imaging abnormality. Persistent symptoms may call for review of both, particularly if the original label of tendinitis no longer fits.
Rehabilitation addresses more than soreness
Rehabilitation can address strength, balance, movement control, and tolerance of progressively more demanding activity. In a small 2025 randomized trial involving amateur athletes with chronic ankle instability, balance training and dynamic neuromuscular stabilization improved several functional measures more than conventional training. Forty people were randomized and 36 completed the study. Its short follow-up and small groups limit broad conclusions, but it supports attention to function rather than pain alone. (2)
Heidi’s report of knee symptoms also deserves a separate assessment. Altered walking may be relevant, but the call does not establish that her ankle caused her knee pain. Treating one area should not substitute for examining another area that continues to hurt.
Could Wharton’s jelly or umbilical cord blood products have a role?
Patients with persistent ankle pain often want to know whether a donated birth-tissue product could help when rest, medication, or previous treatment has not provided lasting relief. Wharton’s jelly and umbilical cord blood products are being investigated for different biological properties. The possibility deserves a careful discussion, particularly when symptoms involve injured connective tissue. The starting point remains a specific diagnosis: treating an irritated tendon, a mechanically unstable ankle, and a painful subtalar region are different clinical problems.
Wharton’s jelly: why the connective-tissue matrix attracts interest
Wharton’s jelly is the gelatinous connective tissue surrounding the blood vessels inside the umbilical cord. Its extracellular matrix—the material around its cells—contains structural and water-binding components. Researchers are interested in whether processed donor tissue can provide a useful matrix and biological environment for damaged musculoskeletal tissue.
A 2020 laboratory characterization of one cord-derived preparation detected hyaluronic acid, growth factors, cytokines, and membrane-enclosed particles. This supplies a rationale for further research, but it did not test whether patients’ ankle pain improved. Detecting these components does not establish a therapeutic dose or prove ligament regeneration. Processing also matters: one preparation’s findings cannot be assumed to describe every commercial Wharton’s jelly product. The study included commercial affiliations. (3)
A small study closer to the problem: sinus tarsi pain
The sinus tarsi is a space near the outside of the hindfoot, below and in front of the outer ankle bone. Pain there can overlap with a patient’s description of “outside ankle pain,” although it is a different diagnosis from peroneal tendinopathy.
A 2025 case series followed five women with persistent sinus tarsi symptoms after previous conservative care. They received a Wharton’s jelly allograft as part of a program that also included extracorporeal pulse-activated therapy, laser treatment, activity restriction, and mechanical support where indicated. Mean pain scores decreased from 6.8 to 1 at an average of about 80 days.
This is an encouraging early observation, but there was no comparison group, several treatments were combined, and follow-up was short. The study cannot isolate the allograft’s contribution or demonstrate that it rebuilt ligaments. Several authors were affiliated with the tissue manufacturer. These results justify better trials; they do not establish effectiveness for a torn peroneal tendon or recurrent lateral ankle sprains. (4)
Umbilical cord blood products: a different research question
Umbilical cord blood comes from blood remaining in the cord and placenta after delivery. It is distinct from Wharton’s jelly tissue. Depending on processing, a blood-derived preparation may contain cells, plasma or serum components, and soluble proteins. Its contents must be identified rather than inferred from the words “cord blood.”
A 2019 conference abstract reported an early prospective registry of a cord-blood-derived fluid allograft used alongside foot and ankle surgery. The report described successful fusion in 20 of 21 patients assessed for that outcome. This is preliminary surgical-adjunct evidence: patients also underwent surgery and bone grafting, and there was no untreated comparison group to show the product’s added benefit. It does not establish that a cord-blood injection alone treats ankle weakness, heals peroneal tendinopathy, or prevents surgery. (5)
“Cord-derived” does not identify what is being injected
| Preparation | Key distinction |
|---|---|
| Wharton’s jelly tissue allograft | Processed donor connective tissue; composition and viable-cell content depend on the specific preparation. |
| Cord-blood-derived product | Blood-derived preparation; not the cord’s connective-tissue matrix. |
| Culture-expanded cord-derived cells | Cells isolated and multiplied in a laboratory. Findings cannot be transferred to non-expanded tissue or blood products. |
| Isolated exosome product | A separately prepared vesicle product. Tissue containing vesicle-sized particles is not equivalent to a characterized exosome treatment. |
Neither a donor’s young age nor the label “stem cell” establishes that a finished product contains a clinically meaningful number of living stem cells. A useful discussion identifies the exact preparation, what it contains, the proposed target, and evidence for that product in that diagnosis.
Safety and regulatory status are part of the decision
Wharton’s jelly and umbilical cord blood products have not been FDA-approved to treat orthopedic conditions such as ankle tendon or ligament injuries. FDA registration, donor screening, or a listing on ClinicalTrials.gov does not establish approval or proven effectiveness. Investigational use requires the applicable regulatory oversight. Potential risks include infection, inflammatory or immune reactions, and failure to improve; donor origin does not make a product risk-free. (6)
For a patient with continuing lateral ankle pain, these products are therefore a research discussion rather than an established substitute for rehabilitation or necessary repair. Larger controlled trials need to show whether they improve pain, stability, function, and return to activity beyond the care patients already receive.
Where do PRP, prolotherapy, and bone marrow treatments fit?
In my radio discussion, I described injection treatments considered in my practice. Clinical experience can help frame a discussion, but it does not establish that every lateral ankle problem responds to the same injection. PRP uses a preparation from the patient’s blood, and bone marrow concentrate uses the patient’s marrow. These are different from donated Wharton’s jelly and cord-blood products; evidence for one preparation cannot establish the effectiveness of another.
For peroneal tendinopathy specifically, the 2018 ESSKA-AFAS panel found insufficient evidence to support PRP. That historical conclusion should be distinguished from research involving other tendons, ankle arthritis, or ligament injuries. Results from one diagnosis cannot be assumed to apply to another. (1)
A newer placebo-controlled trial of dextrose prolotherapy studied 114 people with chronic ankle instability. Some secondary outcomes—dynamic balance and recurrent sprains—favored dextrose. However, the groups did not differ significantly on the primary ankle-instability questionnaire outcome. This is a promising but mixed result for a particular ligament-related condition, not proof that injections repair all causes of ankle pain. (7)
These studies also do not demonstrate that bone marrow concentrate reliably regrows a torn peroneal tendon or that adding different products guarantees better results. A discussion of injections should identify the diagnosis, the product, the intended outcome, and the evidence relevant to that combination.
What should improvement look like?
Useful goals include walking more comfortably, fewer episodes of giving way, better balance, and improved tolerance of the movements required for work or sport. Improvement should be assessed over time rather than inferred from soreness after a procedure.
A new injury with inability to bear weight, marked swelling, deformity, or rapidly worsening symptoms needs prompt assessment. (8) A persistently painful ankle also deserves reassessment when a treatment course is not producing a meaningful functional change.
For Heidi and Stephen’s friend, the next useful step would be a specific diagnosis. My discussion with the callers identifies questions to investigate. It does not establish that either person had a confirmed tendon tear or a documented response to treatment. For someone considering a donor-derived product, the practical question is whether research on that exact preparation supports its proposed use for the structure causing the symptoms.
Related reading
- PRP, bone marrow, and Wharton’s jelly: understanding different preparations
- Exosomes and osteoarthritis: a separate research field
- Patellar tendon and cartilage research — a companion discussion involving a different tendon and diagnosis.
References
1 van Dijk PA, Miller D, Calder J, DiGiovanni CW, Kennedy JG, Kerkhoffs GM, Kynsburtg A, Havercamp D, Guillo S, Oliva XM, Pearce CJ, Pereira H, Spennacchio P, Stephen JM, van Dijk CN. The ESSKA-AFAS international consensus statement on peroneal tendon pathologies. Knee Surg Sports Traumatol Arthrosc. 2018;26(10):3096-3107. doi:10.1007/s00167-018-4971-x.
2 Yesilkir S, Ergezen Sahin G. Dynamic neuromuscular stabilization, balance, and conventional training for chronic ankle instability in amateur athletes: a randomised controlled trial. BMC Sports Sci Med Rehabil. 2025;17(1):286. doi:10.1186/s13102-025-01319-8.
3 Gupta A, El-Amin SF III, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020;15:49. doi:10.1186/s13018-020-1553-7.
4 Parker R, Shou J, Woods C, Lambert N, Barrett T. Regenerative Protocol for Ligamentous Defects in Patients with Sinus Tarsitis: A Case Series. Arch Clin Biomed Res. 2025;9:419–423. doi:10.26502/acbr.50170484.
5 Cooper P, Petzold B, Czop S, Sane M, Tang H, Mustafi SB, Jones C. Umbilical Cord Blood-Derived Fluid Allograft Product in Foot and Ankle Surgery: Early Results from a Prospective Registry. Foot Ankle Orthop. 2019;4(4 Suppl). Conference abstract. doi:10.1177/2473011419S00151.
6 U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. June 3, 2021. Accessed November 15, 2026.
7 Sit RW, Wu RW, Reeves KD, Chan DC, Fung CL, Wang B, Law SW, Yip BH, Rabago D. Dextrose Prolotherapy Injection Improves Dynamic Postural Balance and Reduces Risk of Recurrent Sprains in Chronic Ankle Instability: A 1-Year Randomized Placebo-Controlled Trial. Arch Phys Med Rehabil. 2026;107(7):1701-1708. doi:10.1016/j.apmr.2025.11.032.
8 MedlinePlus. Ankle pain. Medical Encyclopedia. U.S. National Library of Medicine. Accessed November 15, 2026.
The post Wharton’s Jelly and Umbilical Cord Blood Products for Outside Ankle Pain: What Does the Research Show? appeared first on Stem Cell Institute.